Service d'Endocrinologie, Hopital Haut-Leveque
Pessac, 33600, France
NCT Number: NCT02889224
Working hypothesis: the interactions between the endogenous endocannabinoïds (ECS) - and cortisol, the end product of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the pathophysiology of Cushing's syndrome.
The investigators speculate that:
* acute or chronic variations in plasma cortisol may induce changes in the activity of the ECS * that there is a circadian rhythm of the ECS driven by the rythm of plasma cortisol
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Pessac, 33600, France
The study aim to identify the relationship between the ECS and the HPA axis in humans with a main objective to assess if Cushing's syndrome induces changes in the ECS activity.
For this purpose:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all patients groups:
" Hypercortisolism " group:
" Obese " group:
" Hydrocortisone " group:
Exclusion criteria
Time frame: Baseline
The primary outcome will be assessed by a measurement of plasma concentration of 2-AG during the circadian rhythm of ACTH/cortisol.
Time frame: Baseline and day 6
The secondary outcome wille be assessed by a measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol.
Time frame: Baseline
Measurement of plasma concentration of AEA, OEA and PEA on 07:30 A.M. ± 1 hour (fasting), 08:00 A.M. ± 1 hour (fasting), 09:00 A.M. ± 1 hour, 10:00 A.M. ± 1 hour, 04:00 P.M. ± 1 hour
Time frame: Baseline
Measurement of plasma concentration of AEA, OEA and PEA during the circadian rhythm of ACTH/cortisol
University Hospital, Bordeaux
Other
Acronym: VISECA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001452
Abnormalities, Multiple, Adrenal Gland Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07282223
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Beijing, China
View Trial DetailsNCT05633953
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Pessac, France
View Trial DetailsNCT03606408
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Aurora, Colorado, United States
View Trial Details